重组改构人肿瘤坏死因子联合TC方案术后辅助治疗非小细胞肺癌的效果  

The efficacy of rmhTNF combined with TC regimen as postoperative adjuvant therapy for non-small-cell lung cancer

作　　者：米丽丽[1] 王伟[2] 王瑞[1] 高峰[1] 张泽峰[1] 郭杨[1] 

机构地区：[1]河北医科大学第四医院,石家庄市050011 [2]河北省成安县人民医院,056700

出　　处：《实用医学杂志》2013年第18期3051-3053,共3页The Journal of Practical Medicine

基　　金：河北省普通高等学校强势特色学科肿瘤学建设经费资助项目(编号:冀教告[2005]52号);河北省科技厅科技支撑计划项目(编号:072761150)

摘　　要：目的:观察非小细胞肺癌(NSCLC)术后化疗联合重组改构人肿瘤坏死因子(rmhTNF)的临床疗效。方法:患者随机分为试验组和对照组各60例。对照组仅给予化疗,试验组在化疗的同时在第1~7天,第11~17天肌肉注射rmhTNF 4×106U/m^2,21 d为1个周期,连用4个周期。随访两组患者的无病生存时间(DFS)及1、2、3和5年生存率。结果:试验组治疗后KPS评分为(83.2±7.5)分,对照组为(79.8±8.9)分(P=0.028)。试验组和对照组Ⅲ+Ⅳ度不良反应发生率差异无显著性(P>0.05)。试验组与对照组中位DFS分别为39.9个月和33.1个月(P<0.05),两组患者术后1、2、3、5年总生存率分别为98.3%、85.0%、64.7%、42.5%和100%、78.3%、46.1%、23.9%;术后平均生存时间分别为44.0个月和37.0个月,差异有统计学意义(P<0.05)。结论:NSCLC术后化疗联合rmhTNF疗效显著优于单纯化疗,可延长生存期改善生存质量。Objective To explore the efficacy of domestic recombinant mutant human tumor necrosis factor （ImhTNF） in combination with docetaxel and carboplatin （TC） as postoperative adjuvant therapy for non-small-cell lung cancer （NSCLC）. Methods 120 patients undergoing radical resection of NSCLC were randomly devided into a study group （60 patients） and a control group （60 patients）. The study group received rmhTNF injections of 4×10^6U/m^2 combined with chemotherapy with TC regimen on days 1 to 7 and days 11 to 17 for 21 days as a chemotherapy cycle; while the control group received chemotherapy with TC regimen alone. All the patients received 4 cycles. The efficacy, toxicity, and differences in disease-free survival （DFS） and overall survival （OS） were was evaluated. Results The KPS scores was 83.2 ± 7.5 in the study group and 79.8 ± 8.9 in the control group （P = 0.028）. m to IV toxicity did not differ significantly between the two groups （P 〉 0.05）. DFS was 39.9 months in the study group and 33.1 months in the control group （P 〈 0.05）. The 1-, 2-, 3-, or 5-year survival rates was 98.3%, 85.0%, 64.7%, 42.5% in the study group and 100%, 78.3%, 46.1%, and 23.9% in the control group. The average survival time was 44.0 months in the study group and 37.0 months in the control group （P 〈 0.05）. Conclusions The efficacy of chemotherapy combined with rmhTNF was remarkably greater than that of chemotherapy alone. Chemotherapy combined with rmhTNF can prolonge the disease-free survival and overall survival and quality of life.

关 键 词：非小细胞肺癌 重组改构人肿瘤坏死因子 联合化疗 无病生存率 生存率 

分 类 号：R734.2[医药卫生—肿瘤]